PDCD1LG2 and lymphoma: Dr. Ogawa and co-workers revealed that a high frequency of PD-L1/PD-L2-involving genetic aberrations was observed in Epstein-Barr virus (EBV)-positive lymphomas (22%), however the frequency was much lower in EBV-negative lymphomas regardless of histology type (5%), suggesting a potential role of detecting PD-L1/PD-L2-involving lesions for these lymphomas to be effectively targeted by immune checkpoint blockade (22).